Markets

Biotech’s Top Funds Are Doubling Down on This Oral Peptide Company (NASDAQ: ENTX)

After joining Entera’s oversubscribed $275 million financing, leading healthcare funds kept adding shares. Their growing positions point to conviction in an oral osteoporosis program with blockbuster potential.

Biotech’s Top Funds Are Doubling Down on This Oral Peptide Company (NASDAQ: ENTX) Sponsored · Market Discovery Content

Third-quarter 13F filings are now in, and for one biotech they reveal something unusual: specialist healthcare funds that had already invested directly in the company kept buying more shares in the market. That company is Entera (NASDAQ: ENTX), a developer of oral peptide therapies. In July, it announced an oversubscribed $275 million private investment in public equity (PIPE). It was led by biotechnology specialist BVF Partners, with Venrock Healthcare Capital Partners, Spruce Street, RA Capital and Perceptive Advisors among the participants.

The PIPE was priced at $2.04 per share. From July 28 through November 17, the stock traded at roughly $2.44 to $3.96, closing November 17 at $3.00, approximately 47% above the deal price. Those original allocations were well in the green. For investors focused on a drug’s long-term potential, holding through that gain would be understandable. What makes the filings particularly interesting is the additional buying.

Several participants kept buying in the market beyond their initial allocations. Venrock’s Schedule 13G showed almost four million additional shares as of October 23, an increase of approximately 81% from its post-PIPE prospectus position. Spruce Street’s September-end holding was roughly 1.4 million shares, or 14%, higher. Nantahala, NEXTBio and Affinity also reported increases of approximately 29%, 25% and 36%. In other words, the PIPE apparently wasn’t enough. The follow-on accumulation echoes the demand behind an already oversubscribed transaction, one described at the time as the largest publicly disclosed Israeli biotech PIPE on record.

Entire exhibit created with image generation. Entera institutional accumulation: Venrock +80.8%; Spruce Street +14.2%; Nantahala +29.1%; NEXTBio +25.3%; Affinity +35.6%. Before and after share counts and net additions reflect SEC filing comparisons.

The opportunity driving the buying

The growing exposure comes as Entera nears the planned initiation of a registrational Phase 3 trial for EB613, the first once-daily oral anabolic, or bone-building, tablet in development for osteoporosis.

The scale matters. An estimated 200 million women worldwide suffer from osteoporosis, and an oral anabolic could expand the market for bone-building treatment beyond the patients currently reached by injections. Entera sees blockbuster sales potential for EB613 in the United States alone.

Approximately 10 million Americans suffer from osteoporosis. An estimated six million diagnosed patients remain untreated. That is the commercial opening for EB613: an oral anabolic could drastically expand the treated market, reaching patients who currently go untreated and potentially enabling earlier intervention before a debilitating fracture occurs.

“There is a white space in osteoporosis,” CEO Miranda Toledano said at Guggenheim on November 9. Existing oral medicines generally slow bone breakdown; anabolic therapies build new bone, but every approved option requires injections. EB613 aims to address that gap by delivering PTH(1-34), or teriparatide, the same bone-building peptide used in Eli Lilly’s (NYSE: LLY) injectable Forteo, through Entera’s proprietary N-Tab oral peptide platform.

Entire exhibit created with image generation. Entera U.S. osteoporosis white-space estimates: approximately 10 million existing diagnosed patients, not annual new diagnoses; approximately 6 million untreated and 4 million treated; injectable anabolic treatment share approximately 15 percent. Reference year not specified in slide 28. Potential EB613 access paths are conceptual, not sales forecasts.

EB613 already has patient efficacy data behind that opportunity. Its six-month, placebo-controlled, dose-ranging Phase 2 study enrolled 161 postmenopausal women with low bone mass or osteoporosis. It met its primary pharmacodynamic, or bone-turnover biomarker, endpoint and secondary bone mineral density endpoints, with increases in bone-formation markers, reductions in bone-resorption markers and gains in lumbar spine, total hip and femoral neck BMD.

A comparative Phase 1 study presented at ENDO 2026 also showed that single-tablet EB613 produced systemic drug exposure and measured biological responses comparable to Forteo. Those results support bringing an established bone-building peptide into a single daily tablet and advancing it into registrational testing.

The pivotal next step is already funded

The FDA has aligned with Entera on a streamlined registrational plan built around a single 12-month, randomized, double-blind, placebo-controlled Phase 3 study. The latest design calls for approximately 900 postmenopausal women with osteoporosis, with percent change in total hip bone mineral density as the primary endpoint. A planned extension would follow patients through month 24. Entera plans a potential New Drug Application under the 505(b)(2) pathway, including a scientific bridge to Forteo.

The pivotal program still has to deliver, but Entera approaches it with clinical data, regulatory alignment and the financing in place. September-end cash of $265.9 million supports a projected runway into 2030, with management expecting resources to fully fund EB613 through the anticipated application submission. First site activation is expected in late 2026; topline results are anticipated in the second half of 2028.

That gives the buying a concrete backdrop: a potential blockbuster oral anabolic with patient efficacy data, an FDA-aligned development path and the capital to execute it. The oversubscribed PIPE brought specialist funds into the story. Their subsequent accumulation suggests some of those same backers wanted a bigger stake ahead of Entera’s pivotal next chapter.


Recent News Highlights from Entera (NASDAQ: ENTX)

Entera Announces Third Quarter 2026 Financial Results and Business Updates

Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors

Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis


Read this Next >>

Alpha Tau's Brain Cancer Therapy Shrank or Cleared Every Evaluable Tumor in Its U.S. Trial